医学
心肾综合症
糖尿病
代谢综合征
肾脏疾病
2型糖尿病
心力衰竭
内科学
人口
协同运输机
内分泌学
钠
化学
环境卫生
有机化学
出处
期刊:Journal of Cardiovascular Pharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2022-05-01
卷期号:79 (5): 593-604
被引量:1
标识
DOI:10.1097/fjc.0000000000001248
摘要
Abstract: Sodium–glucose cotransporter-2 inhibitors were approved as adjunct therapy for the management of type 2 diabetes and have become a high-level recommendation for this population with cardiorenal metabolic syndrome. In addition, evidence continues to grow supporting this class of medications for people with heart failure and chronic kidney disease, regardless of diabetes status. This narrative review summarizes the sodium–glucose cotransporter inhibitors for cardiorenal metabolic syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI